Itamar Medical Ltd., has announced the launch of WatchPAT 300, the next generation WatchPAT system for home sleep apnea testing. WatchPAT 300 includes several advances that are designed to enhance both patients’ WatchPAT experience as well as provide physicians with a trusted and cost-effective method for rapid, scalable and effective diagnosis of sleep apnea.
Background
Itamar Medical develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market. Last appearing on our pages almost a year ago with its new WatchPAT™ Sleep Apnea Scoring Guidelines, the company now tells us about its new WatchPAT 300 sleep apnea device.
WatchPAT 300 utilizes peripheral arterial tone and other signals to calculate True Sleep Time and Complete Sleep Architecture to accurately and reliably diagnose both obstructive and central sleep apnea.
Itamar points to an intuitive and more comfortable design with three points of contact and without a cumbersome nasal cannula or chest belts to ensure patient ease of use. It is based on the peripheral arterial tone signal (PAT) and uses its advanced actigraphy to differentiate between wake and sleep periods to calculate true sleep time. WatchPAT 300 also uses the PAT amplitude and pulse rate to differentiate between non-rapid eye movement (REM) and REM sleep. It also provides clinically validated sleep architecture, based on sleep stages, including sleep efficiency, sleep latency and REM latency. Its total sleep time reduces the risk of misdiagnosis and misclassification that has been reported to be 20 percent in studies using total recording time. WatchPAT 300 also includes a Central+ module, which enables specific identification for Central Sleep Apnea events. Its one-stop preparation comes with a significantly faster download and automated study preparation time to improve workflow.
WatchPAT 300 was granted U.S. FDA 510(k) clearance on August 17, 2018 and will gradually replace the current WatchPAT 200 platform. It will be presented at SLEEP 2019 on June 8-12 in San Antonio, TX.
Company comments
“Sleep apnea has reached epidemic levels and is estimated to affect 25 percent of adults worldwide,” said Gilad Glick, President and CEO of Itamar Medical. “This has significant health and economic implications, as half of all patients with cardiovascular disease are believed to suffer from sleep apnea and the total cost of unmanaged obstructive sleep apnea is $150 billion each year in the United States alone. Addressing the challenge of efficiently and cost-effectively diagnosing the millions of patients with undiagnosed sleep apnea requires a simple, accurate and scalable modality. We believe that WatchPAT 300 – which demonstrates Itamar Medical’s continued commitment to innovation focused on meeting the needs of patients, health systems, payers and physicians – can play a critical role in solving this challenge.”
Source: Itamar Medical Ltd.
published: April 3, 2019 in: Launches / Withdrawals, Monitoring, Technology